Mainz Biomed shares surge 11.34% intraday after presenting pancreatic cancer study results at AACR 2026.

Mainz Biomed surged 11.34% intraday following the announcement that it will present results of its pancreatic cancer verification study at the AACR 2026 Annual Meeting. This event, a major oncology conference, highlights progress in the company’s pipeline for next-generation cancer screening. The move aligns with a series of recent positive developments, including the commercial launch of ColoAlert® in Switzerland, regulatory approvals in the UK, and partnerships to expand diagnostic solutions in South America and Germany. These milestones reinforce investor confidence in Mainz Biomed’s growth trajectory and its focus on colorectal and pancreatic cancer detection. The intraday rally reflects optimism around the company’s advancing product portfolio and strategic collaborations, which position it to capture market share in the expanding non-invasive cancer screening sector.